About this Journal Submit a Manuscript Table of Contents
Journal of Ophthalmology
Volume 2010 (2010), Article ID 175163, 9 pages
http://dx.doi.org/10.1155/2010/175163
Review Article

ROCK as a Therapeutic Target of Diabetic Retinopathy

Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka 812-8582, Japan

Received 2 December 2009; Accepted 9 April 2010

Academic Editor: Kavita Hegde

Copyright © 2010 Ryoichi Arita et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. H. Kempen, B. J. O'Colmain, M. C. Leske, et al., “The prevalence of diabetic retinopathy among adults in the United States,” Archives of Ophthalmology, vol. 122, no. 4, pp. 552–563, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. H. King, R. E. Aubert, and W. H. Herman, “Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections,” Diabetes Care, vol. 21, no. 9, pp. 1414–1431, 1998. View at Scopus
  3. “Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group,” Ophthalmology, vol. 98, pp. 766–785, 1991.
  4. L. P. Aiello, “Angiogenic pathways in diabetic retinopathy,” The New England Journal of Medicine, vol. 353, no. 8, pp. 839–841, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. D. S. Fong, L. Aiello, T. W. Gardner, et al., “Diabetic retinopathy,” Diabetes Care, vol. 26, no. 1, pp. S99–S102, 2003. View at Scopus
  6. A. M. Joussen, T. Murata, A. Tsujikawa, B. Kirchhof, S.-E. Bursell, and A. P. Adamis, “Leukocyte-mediated endothelial cell injury and death in the diabetic retina,” American Journal of Pathology, vol. 158, no. 1, pp. 147–152, 2001. View at Scopus
  7. C. W. Smith, S. D. Marlin, R. Rothlein, C. Toman, and D. C. Anderson, “Cooperative interactions of LFA-1 and Mac-1 with intracellular adhesion molecule-1 in facilitating adherence and transendothelial migration of human neutrophils in vitro,” Journal of Clinical Investigation, vol. 83, no. 6, pp. 2008–2017, 1989. View at Scopus
  8. F. C. Barouch, K. Miyamoto, J. R. Allport, et al., “Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes,” Investigative Ophthalmology and Visual Science, vol. 41, no. 5, pp. 1153–1158, 2000. View at Scopus
  9. A. M. Joussen, V. Poulaki, N. Mitsiades, et al., “Suppression of Fas-FasL-induced endothelial cell apoptosis prevents diabetic blood-retinal barrier breakdown in a model of streptozotocin-induced diabetes,” The FASEB Journal, vol. 17, no. 1, pp. 76–78, 2003. View at Scopus
  10. R. Arita, Y. Hata, S. Nakao, et al., “Rho kinase inhibition by fasudil ameliorates diabetes-induced microvascular damage,” Diabetes, vol. 58, no. 1, pp. 215–226, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. N. Ferrara, “Vascular endothelial growth factor: basic science and clinical progress,” Endocrine Reviews, vol. 25, no. 4, pp. 581–611, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. A. P. Adamis and D. T. Shima, “The role of vascular endothelial growth factor in ocular health and disease,” Retina, vol. 25, no. 2, pp. 111–118, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Moradian, H. Ahmadieh, M. Malihi, M. Soheilian, M. H. Dehghan, and M. Azarmina, “Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 246, no. 12, pp. 1699–1705, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. C. Shima, H. Sakaguchi, F. Gomi, et al., “Complications in patients after intravitreal injection of bevacizumab,” Acta Ophthalmologica, vol. 86, no. 4, pp. 372–376, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. B. P. Eliceiri, R. Klemke, S. Stromblad, and D. A. Cheresh, “Integrin αvβ3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis,” Journal of Cell Biology, vol. 140, no. 5, pp. 1255–1263, 1998. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Mavria, Y. Vercoulen, M. Yeo, et al., “ERK-MAPK signaling opposes Rho-kinase to promote endothelial cell survival and sprouting during angiogenesis,” Cancer Cell, vol. 9, no. 1, pp. 33–44, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. G. P. van Nieuw Amerongen, P. Koolwijk, A. Versteilen, and V. W. M. Van Hinsbergh, “Involvement of RhoA/Rho kinase signaling in VEGF-induced endothelial cell migration and angiogenesis in vitro,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 2, pp. 211–217, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. Y. Noda, Y. Hata, T. Hisatomi, et al., “Functional properties of hyalocytes under PDGF-rich conditions,” Investigative Ophthalmology and Visual Science, vol. 45, no. 7, pp. 2107–2114, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Hirayama, Y. Hata, Y. Noda, et al., “The involvement of the Rho-kinase pathway and its regulation in cytokine-induced collagen gel contraction by hyalocytes,” Investigative Ophthalmology and Visual Science, vol. 45, no. 11, pp. 3896–3903, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. T. Kita, Y. Hata, K. Kano, et al., “Transforming growth factor-β2 and connective tissue growth factor in proliferative vitreoretinal diseases: possible involvement of hyalocytes and therapeutic potential of rho kinase inhibitor,” Diabetes, vol. 56, no. 1, pp. 231–238, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. K. E. Kamm and J. T. Stull, “The function of myosin and myosin light chain kinase phosphorylation in smooth muscle,” Annual Review of Pharmacology and Toxicology, vol. 25, pp. 593–620, 1985. View at Scopus
  22. Y. Fukata, K. Kaibuchi, M. Amano, and K. Kaibuchi, “Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells,” Trends in Pharmacological Sciences, vol. 22, no. 1, pp. 32–39, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. T. Kita, Y. Hata, R. Arita, et al., “Role of TGF-β in proliferative vitreoretinal diseases and ROCK as a therapeutic target,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 45, pp. 17504–17509, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. K. Kaibuchi, S. Kuroda, and M. Amano, “Regulation of the cytoskeleton and cell adhesion by the Rho family GTPases in mammalian cells,” Annual Review of Biochemistry, vol. 68, pp. 459–486, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. H. Iwasaki, R. Okamoto, S. Kato, et al., “High glucose induces plasminogen activator inhibitor-1 expression through Rho/Rho-kinase-mediated NF-κB activation in bovine aortic endothelial cells,” Atherosclerosis, vol. 196, no. 1, pp. 22–28, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. V. Kolavennu, L. Zeng, H. Peng, Y. Wang, and F. R. Danesh, “Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control,” Diabetes, vol. 57, no. 3, pp. 714–723, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. J. Tang, I. Kusaka, A. R. Massey, S. Rollins, and J. H. Zhang, “Increased RhoA translocation in aorta of diabetic rats,” Acta Pharmacologica Sinica, vol. 27, no. 5, pp. 543–548, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. H. Lee, I. L. Chi, J.-J. Liao, et al., “Lysophospholipids increase ICAM-1 expression in HUVEC through a G i- and NF-κB-dependent mechanism,” American Journal of Physiology, vol. 287, no. 6, pp. C1657–C1666, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. B. Wojciak-Stothard, L. Williams, and A. J. Ridley, “Monocyte adhesion and spreading on human endothelial cells is dependent on Rho-regulated receptor clustering,” Journal of Cell Biology, vol. 145, no. 6, pp. 1293–1307, 1999. View at Publisher · View at Google Scholar · View at Scopus
  30. C. Giagulli, E. Scarpini, L. Ottoboni, et al., “RhoA and ζ PKC control distinct modalities of LFA-1 activation by chemokines: critical role of LFA-1 affinity triggering in lymphocyte in vivo homing,” Immunity, vol. 20, no. 1, pp. 25–35, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. O. Barreiro, M. Yanez-Mo, J. M. Serrador, et al., “Dynamic interaction of VCAM-1 and ICAM-1 with moesin and ezrin in a novel endothelial docking structure for adherent leukocytes,” Journal of Cell Biology, vol. 157, no. 7, pp. 1233–1245, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. D. J. G. Mackay, F. Esch, H. Furthmayr, and A. Hall, “Rho- and Rac-dependent assembly of focal adhesion complexes and actin filaments in permeabilized fibroblasts: an essential role for ezrin/radixin/moesin proteins,” Journal of Cell Biology, vol. 138, no. 4, pp. 927–938, 1997. View at Publisher · View at Google Scholar · View at Scopus
  33. L. Zeng, H. Xu, T.-L. Chew, et al., “HMG CoA reductase inhibition modulates VEGF-induced endothelial cell hyperpermeability by preventing RhoA activation and myosin regulatory light chain phosphorylation,” FASEB Journal, vol. 19, no. 13, pp. 1845–1847, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. M. V. Hoang, M. C. Whelan, and D. R. Senger, “Rho activity critically and selectively regulates endothelial cell organization during angiogenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 7, pp. 1874–1879, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. J.-M. Hyvelin, K. Howell, A. Nichol, C. M. Costello, R. J. Preston, and P. McLoughlin, “Inhibition of Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation,” Circulation Research, vol. 97, no. 2, pp. 185–191, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. H. Shimokawa and M. Rashid, “Development of Rho-kinase inhibitors for cardiovascular medicine,” Trends in Pharmacological Sciences, vol. 28, no. 6, pp. 296–302, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. M. Shibuya, Y. Suzuki, K. Sugita, et al., “Dose escalation trial of a novel calcium antagonist, AT877, in patients with aneurysmal subarachnoid haemorrhage,” Acta Neurochirurgica, vol. 107, no. 1-2, pp. 11–15, 1990. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Shibuya, S. Hirai, M. Seto, S.-I. Satoh, and E. Ohtomo, “Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial,” Journal of the Neurological Sciences, vol. 238, no. 1-2, pp. 31–39, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. X.-F. Ming, H. Viswambharan, C. Barandier, et al., “Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells,” Molecular and Cellular Biology, vol. 22, no. 24, pp. 8467–8477, 2002. View at Publisher · View at Google Scholar · View at Scopus
  40. J. Marin and M. A. Rodriguez-Martinez, “Role of vascular nitric oxide in physiological and pathological conditions,” Pharmacology and Therapeutics, vol. 75, no. 2, pp. 111–134, 1997. View at Publisher · View at Google Scholar · View at Scopus
  41. L. Rossig, B. Fichtlscherer, K. Breitschopf, et al., “Nitric oxide inhibits caspase-3 by S-nitrosation in vivo,” The Journal of Biological Chemistry, vol. 274, no. 11, pp. 6823–6826, 1999. View at Publisher · View at Google Scholar · View at Scopus
  42. L. Rossig, J. Haendeler, C. Hermann, et al., “Nitric oxide down-regulates MKP-3 mRNA levels: involvement in endothelial cell protection from apoptosis,” The Journal of Biological Chemistry, vol. 275, no. 33, pp. 25502–25507, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. Y. Hata, M. Miura, S. Nakao, S. Kawahara, T. Kita, and T. Ishibashi, “Antiangiogenic properties of fasudil, a potent Rho-kinase inhibitor,” Japanese Journal of Ophthalmology, vol. 52, no. 1, pp. 16–23, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. J. Molgaard, H. von Schenck, and A. G. Olsson, “Effects of simvastatin on plasma lipid, lipoprotein and apolipoprotein concentrations in hypercholesterolaemia,” European Heart Journal, vol. 9, no. 5, pp. 541–551, 1988. View at Scopus
  45. L. Van Aelst and C. D'Souza-Schorey, “Rho GTPases and signaling networks,” Genes and Development, vol. 11, no. 18, pp. 2295–2322, 1997. View at Scopus
  46. S. Kawahara, Y. Hata, T. Kita, et al., “Potent inhibition of cicatricial contraction in proliferative vitreoretinal diseases by statins,” Diabetes, vol. 57, no. 10, pp. 2784–2793, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. A. Masumoto, M. Mohri, H. Shimokawa, L. Urakami, M. Usui, and A. Takeshita, “Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina,” Circulation, vol. 105, no. 13, pp. 1545–1547, 2002. View at Publisher · View at Google Scholar · View at Scopus
  48. N. Okamura, M. Saito, A. Mori, et al., “Vasodilator effects of fasudil, a Rho-kinase inhibitor, on retinal arterioles in stroke-prone spontaneously hypertensive rats,” Journal of Ocular Pharmacology and Therapeutics, vol. 23, no. 3, pp. 207–212, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. A. Masumoto, Y. Hirooka, H. Shimokawa, K. Hironaga, S. Setoguchi, and A. Takeshita, “Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans,” Hypertension, vol. 38, no. 6, pp. 1307–1310, 2001. View at Scopus
  50. A. J. Barber, “A new view of diabetic retinopathy: a neurodegenerative disease of the eye,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 27, no. 2, pp. 283–290, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. V. Parisi and L. Uccioli, “Visual electrophysiological responses in persons with type 1 diabetes,” Diabetes/Metabolism Research and Reviews, vol. 17, no. 1, pp. 12–18, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. E. Lieth, T. W. Gardner, A. J. Barber, and D. A. Antonetti, “Retinal neurodegeneration: early pathology in diabetes,” Clinical and Experimental Ophthalmology, vol. 28, no. 1, pp. 3–8, 2000. View at Publisher · View at Google Scholar · View at Scopus
  53. B. K. Mueller, H. Mack, and N. Teusch, “Rho kinase, a promising drug target for neurological disorders,” Nature Reviews Drug Discovery, vol. 4, no. 5, pp. 387–398, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  54. Y. Kitaoka, Y. Kitaoka, T. Kumai, et al., “Involvement of RhoA and possible neuroprotective effect of fasudil, a Rho kinase inhibitor, in NMDA-induced neurotoxicity in the rat retina,” Brain Research, vol. 1018, no. 1, pp. 111–118, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. P. Lingor, N. Teusch, K. Schwarz, et al., “Inhibition of Rho kinase (ROCK) increases neurite outgrowth on chondroitin sulphate proteoglycan in vitro and axonal regeneration in the adult optic nerve in vivo,” Journal of Neurochemistry, vol. 103, no. 1, pp. 181–189, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. A. Hirata, M. Inatani, Y. Inomata, et al., “Y-27632, a Rho-associated protein kinase inhibitor, attenuates neuronal cell death after transient retinal ischemia,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 246, no. 1, pp. 51–59, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. A. Tura, F. Schuettauf, P. P. Monnier, K. U. Bartz-Schmidt, and S. Henke-Fahle, “Efficacy of Rho-kinase inhibition in promoting cell survival and reducing reactive gliosis in the rodent retina,” Investigative Ophthalmology & Visual Science, vol. 50, no. 1, pp. 452–461, 2009. View at Scopus